Yunfeng Lin is a Second-Level Professor, Chief Physician, and Doctoral Supervisor. He serves as the Deputy Director of the State Key Laboratory of Oral Diseases, Deputy Party Secretary of the West China School of Stomatology at Sichuan University, and Chief Specialist in Maxillofacial Surgery at West China Hospital of Stomatology. Lin has been recognized as a Changjiang Scholar Distinguished Professor, selected for the Ten Thousand Talents Program by the Organization Department of the Central Committee, and awarded the National Health and Medical Outstanding Contribution Expert for Young and Middle-aged Professionals. He has also been named a Leading Talent in Scientific and Technological Innovation by the Ministry of Science and Technology, received the National Award for Outstanding Doctoral Dissertations, and was included in the New Century Excellent Talents Program by the Ministry of Education, as well as other prestigious programs such as the Tianfu Ten-Thousand Talents Program, Sichuan Academic and Technological Leaders, and Sichuan Provincial Health Leaders.

Lin has earned over ten significant awards, including the International Association for Dental Research (IADR) Distinguished Scientist Award, the China Youth Science and Technology Award, the Second Prize in Natural Science from the Ministry of Education, the Second Prize in Scientific and Technological Progress from the Ministry of Education, the National Award for Outstanding Doctoral Dissertations, the Chinese Medical Association Youth Science and Technology Award, the Second Prize in Stomatological Science and Technology from the Chinese Stomatological Association, and the Sichuan Province Innovation and Excellence Medal.

His research focuses on nucleic acid nanomaterials and oral tissue regeneration. Lin has published 240 SCI-indexed articles as corresponding or first author, with an average impact factor exceeding 10. His works include 3 F1000-recommended papers, 23 cover articles, 8 ESI Hot Papers, and 29 ESI Highly Cited Papers, with over 14,000 citations. He has consistently been recognized as one of Elsevier's Most Cited Chinese Researchers and is ranked among the top 2% of scientists globally. Lin has also edited eight English monographs.

In terms of technological innovations, Lin has applied for 112 Chinese invention patents, been granted two U.S. patents, and applied for five international PCT patents. He holds 50 granted Chinese invention patents, with nine transferred patents and 71 patents under active implementation. He has twice won Excellence Awards in the Ministry of Science and Technology's National Disruptive Technology Innovation Competition and an Excellence Award in the cutting-edge biopharmaceutical field at the 2023 Golden Panda Global Innovation and Entrepreneurship Competition. Four of his innovative Class 1.1 drugs are in the preclinical stage, and one is expected to enter clinical trials in 2024. He successfully completed the first U.S. Drug Master File (DMF) registration for a framework nucleic acid drug (FDA: MFO39406) and the first pre-IND application for a framework nucleic acid drug (China's National Medical Products Administration: 2024000818).

Lin also serves in multiple academic roles. He is the Executive Editor of Bone Research and Cell Proliferation, an Editorial Board Member of the Journal of Dental Research, and a Fellow of the International College of Dentists. He holds leadership positions in various academic and professional organizations, including serving as Vice Chairman of the Scientific Research Management Committee of the Chinese Stomatological Association, Vice President of the Tissue Regeneration Branch of the China Association of Medical Equipment, Standing Committee Member of the Oral Biology Branch of the Chinese Stomatological Association, Vice President of the Sichuan Youth Science and Technology Federation, Vice President and Secretary-General of the Sichuan Stomatological Association, and Chairman of the Oral Materials Committee of the Sichuan Stomatological Association.

Chunhai Fan, Chief Scientist at the National Center for Translational Medicine, Tang Zhongying, focuses on the research of ordered interface construction and biological applications of DNA nanotechnology. He is an Academician of the Chinese Academy of Sciences, a Central Committee Member of the Jiu San Society, Dean of the School of Chemistry and Chemical Engineering at Shanghai Jiao Tong University, Executive Dean of the Translational Medicine Research Institute, and Chief Scientist for the Major Science and Technology Projects (Nanotechnology) of the Ministry of Science and Technology. He is also a Fellow of the American Association for the Advancement of Science (AAAS), the International Electrochemical Society, the American Institute for Medical and Biological Engineering, and the Royal Society of Chemistry in the UK. He has received the He Liang He Li Foundation Science and Technology Innovation Award and was selected as a New Cornerstone Investigator for 2023.

He has led his team in developing a new method for precise nanoscale mineralization induced by DNA self-assembly structures, achieving a significant breakthrough in DNA nanotechnology by Chinese researchers, as published in Nature. Additionally, he has been continuously listed as a “Highly Cited Researcher” globally for the past seven years and was elected as an Academician of the Chinese Academy of Sciences at the age of 45, making him the youngest Academician in Shanghai.

Academician Fan’s research encompasses fundamental studies on DNA self-assembly, DNA storage, and molecular machines, as well as translating these findings into clinical applications to benefit human health. He has published over 400 papers in SCI journals, including Nature and Science sub-journals, with over 30,000 citations. His achievements extend beyond academic research; he is dedicated to translating scientific results into practical applications, contributing to society and human health. Academician Fan is involved in the overall design and directional guidance of tetrahedral framework nucleic acid drug systems and serves as the Chair of the Global Tetrahedral Framework Nucleic Acid Industry Development Forum.

Professor Delun Luo has served as an advisor at the Ophthalmology Research Institute of Shanghai Jiao Tong University, Vice President of Jingze Biomedicine (Hefei) Co., Ltd., Managing Director of Chengdu Jingrunze Gene Technology Co., Ltd., Managing Director of Chengdu Nuon Gene Technology Co., Ltd., Deputy Director of the Enterprise Technology Center and Medical Department Director at Chengdu Kanghong Pharmaceutical Group, Deputy General Manager at Kanghong Biotech, and Senior Project Manager at Chengdu Huashen Group. He has been involved in and led the research and development of over 20 national class 1 new drugs. These include:

• Likatin (Iodine [131I] Metuximab Injection), the world’s first monoclonal antibody-based targeted therapy for liver cancer, which has been launched.
• Langmu (Conbercept Injection), which has accumulated sales exceeding 10 billion RMB.
• 1 biologic drug application for NDA.
• 3 drugs in Phase III clinical trials.
• 3 drugs in Phase I clinical trials.
• 6 drugs in preclinical research.

He successfully completed the global first tetrahedral framework nucleic acid drug’s API registration in the US (FDA: MFO39406) and Pre-IND application in China (Application No: 2024000818).

Professor Luo has been comprehensively involved in and responsible for multiple new drugs throughout the entire process, from molecular construction and preclinical and clinical development to regulatory approval and product launch, possessing extensive clinical and project development experience. He has applied for 27 patents, with 9 granted and 8 PCT applications. He has led and participated in over 20 national and provincial-level projects, including the National 973 Program, the "11th Five-Year Plan," and the "12th Five-Year Plan" major national new drug creation projects, with total project funding exceeding 30 million RMB.

Professor Rong Li has over 30 years of experience in new drug registration, application, and development management. She has been involved in the research and development of nine biologic innovative new drugs, including Conbercept Injection, Iodine [131I] Metuximab Injection, and Vascular Epidermal Growth Factor Eye Drops. She has held positions such as Vice President at Sichuan Huashen Group, Executive Deputy Director of the Enterprise Technology Center at Chengdu Kanghong Pharmaceutical Group, and Vice President of Operations at Chengdu XianDao.

With extensive experience in new drug development, IND/NDA registration applications, and R&D management, Professor Li has a deep understanding of national medical policies and drug regulations, particularly in new drug registration strategies and related laws. She possesses strong scientific insight, registration strategy expertise, and application capabilities, and has trained a number of key personnel in registration and government affairs for pharmaceutical companies in Sichuan.

Among the nine innovative drugs Professor Li has been responsible for or involved in, 4 have received new drug certificates, and 2 class 1 biologic innovative drugs are already on the market. She has long served as a project evaluation expert for innovation work in Sichuan Province and Chengdu City, organizing and participating in numerous national and provincial-level projects, including several major national new drug creation projects, national innovation capability construction projects, national high-tech industrialization projects, Sichuan Province strategic emerging industry projects, and science and technology support projects.